Phage Display As a Medium for Target Therapy Based Drug Discovery, Review and Update

Overview

Journal Mol Biotechnol

Publisher Springer

Specialties Biotechnology
Molecular Biology

Date 2024 Jun 1

PMID 38822912

Authors

Samaneh Jahandar-Lashaki

Safar Farajnia

Aref Faraji-Barhagh

Zahra Hosseini

Nasim Bakhtiyari

Leila Rahbarnia

Affiliations

Soon will be listed here.

Abstract

Phage libraries are now amongst the most prominent approaches for the identification of high-affinity antibodies/peptides from billions of displayed phages in a specific library through the biopanning process. Due to its ability to discover potential therapeutic candidates that bind specifically to targets, phage display has gained considerable attention in targeted therapy. Using this approach, peptides with high-affinity and specificity can be identified for potential therapeutic or diagnostic use. Furthermore, phage libraries can be used to rapidly screen and identify novel antibodies to develop immunotherapeutics. The Food and Drug Administration (FDA) has approved several phage display-derived peptides and antibodies for the treatment of different diseases. In the current review, we provided a comprehensive insight into the role of phage display-derived peptides and antibodies in the treatment of different diseases including cancers, infectious diseases and neurological disorders. We also explored the applications of phage display in targeted drug delivery, gene therapy, and CAR T-cell.

Citing Articles

Affinity Peptide-Based Circularly Permuted Fluorescent Protein Biosensors for Non-Small Cell Lung Cancer Diagnosis.

Xu D, Jiang Q, Li Z, Shang A, Liu J, Xue C Sensors (Basel). 2025; 24(24.

PMID: 39771637 PMC: 11679068. DOI: 10.3390/s24247899.

Engineered M13-Derived Bacteriophages Capable of Gold Nanoparticle Synthesis and Nanogold Manipulations.

Karczewska-Golec J, Sadowska K, Golec P, Karczewski J, Wegrzyn G Int J Mol Sci. 2024; 25(20).

PMID: 39457002 PMC: 11508339. DOI: 10.3390/ijms252011222.

References

Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G . Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther. 2022; 7(1):48. PMC: 8844085. DOI: 10.1038/s41392-022-00904-4. View

Azzazy H, Highsmith Jr W . Phage display technology: clinical applications and recent innovations. Clin Biochem. 2002; 35(6):425-45. DOI: 10.1016/s0009-9120(02)00343-0. View

Foglizzo V, Marchio S . Bacteriophages as Therapeutic and Diagnostic Vehicles in Cancer. Pharmaceuticals (Basel). 2021; 14(2). PMC: 7923149. DOI: 10.3390/ph14020161. View

Wu C, Liu I, Lu R, Wu H . Advancement and applications of peptide phage display technology in biomedical science. J Biomed Sci. 2016; 23:8. PMC: 4717660. DOI: 10.1186/s12929-016-0223-x. View

Smith G . Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. 1985; 228(4705):1315-7. DOI: 10.1126/science.4001944. View

Parmley S, Smith G . Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene. 1988; 73(2):305-18. DOI: 10.1016/0378-1119(88)90495-7. View

Barderas R, Benito-Pena E . The 2018 Nobel Prize in Chemistry: phage display of peptides and antibodies. Anal Bioanal Chem. 2019; 411(12):2475-2479. DOI: 10.1007/s00216-019-01714-4. View

Scott J, Smith G . Searching for peptide ligands with an epitope library. Science. 1990; 249(4967):386-90. DOI: 10.1126/science.1696028. View

Devlin J, Panganiban L, Devlin P . Random peptide libraries: a source of specific protein binding molecules. Science. 1990; 249(4967):404-6. DOI: 10.1126/science.2143033. View

10.

McCafferty J, Griffiths A, Winter G, Chiswell D . Phage antibodies: filamentous phage displaying antibody variable domains. Nature. 1990; 348(6301):552-4. DOI: 10.1038/348552a0. View

11.

Willats W . Phage display: practicalities and prospects. Plant Mol Biol. 2003; 50(6):837-54. DOI: 10.1023/a:1021215516430. View

12.

Sioud M . Phage Display Libraries: From Binders to Targeted Drug Delivery and Human Therapeutics. Mol Biotechnol. 2019; 61(4):286-303. DOI: 10.1007/s12033-019-00156-8. View

13.

Jaroszewicz W, Morcinek-Orlowska J, Pierzynowska K, Gaffke L, Wegrzyn G . Phage display and other peptide display technologies. FEMS Microbiol Rev. 2021; 46(2). DOI: 10.1093/femsre/fuab052. View

14.

Alfaleh M, Alsaab H, Mahmoud A, Alkayyal A, Jones M, Mahler S . Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. Front Immunol. 2020; 11:1986. PMC: 7485114. DOI: 10.3389/fimmu.2020.01986. View

15.

Omidfar K, Daneshpour M . Advances in phage display technology for drug discovery. Expert Opin Drug Discov. 2015; 10(6):651-69. DOI: 10.1517/17460441.2015.1037738. View

16.

Zhao Y, Wang Q, Jin Y, Li Y, Nie C, Huang P . Discovery and Characterization of a High-Affinity Small Peptide Ligand, H1, Targeting FGFR2IIIc for Skin Wound Healing. Cell Physiol Biochem. 2018; 49(3):1033-1048. DOI: 10.1159/000493287. View

17.

Kim S, Kim D, Jung H, Lee I, Kim J, Suh J . Bio-inspired design and potential biomedical applications of a novel class of high-affinity peptides. Angew Chem Int Ed Engl. 2012; 51(8):1890-4. DOI: 10.1002/anie.201107894. View

18.

Pleiko K, Posnograjeva K, Haugas M, Paiste P, Tobi A, Kurm K . In vivo phage display: identification of organ-specific peptides using deep sequencing and differential profiling across tissues. Nucleic Acids Res. 2021; 49(7):e38. PMC: 8053097. DOI: 10.1093/nar/gkaa1279. View

19.

Ludtke J, Sololoff A, Wong S, Zhang G, Wolff J . In vivo selection and validation of liver-specific ligands using a new T7 phage peptide display system. Drug Deliv. 2007; 14(6):357-69. DOI: 10.1080/10717540601098765. View

20.

Gregorc V, Santoro A, Bennicelli E, Punt C, Citterio G, Timmer-Bonte J . Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br J Cancer. 2009; 101(2):219-24. PMC: 2720203. DOI: 10.1038/sj.bjc.6605162. View